| Revision as of 01:28, 11 February 2013 editStar767 (talk | contribs)3,516 edits added Category:Living people using HotCat← Previous edit | Revision as of 21:48, 19 February 2013 edit undoCindamuse (talk | contribs)32,512 edits cleanup-reorganize-copyedit; rm POV and unreliable sources, i.e., press releases and promotional websiteNext edit → | ||
| Line 1: | Line 1: | ||
| {{ |
{{BLP sources|date=February 2013}} | ||
| {{third-party|date=February 2013}} | |||
| '''Richard Barker''' is currently Director of the ] (CASMI).<ref name=CASMI>{{cite web|title=Dr Richard Barker OBE|url=http://casmi.org.uk/dr-richard-barker/|publisher=CASMI|accessdate=11 February 2013}}</ref> He has devoted much of his career to improving the process of bringing medical innovations to patients, both in the course of a long business career and as a contributor to academic research and public policy.<ref name=innovativiondebate>{{cite web|title=Dr Richard W. Barker|url=http://www.innovationdebate.com/debate/panelists/dr-richard-barker/|publisher=innovativiondebate.com|accessdate=10 February 2013}}</ref> | |||
| '''Richard Barker''' is a ] healthcare professional. He is known as the Director of the ] (CASMI).<ref name=CASMI>{{cite web|title=Dr Richard Barker OBE|url=http://casmi.org.uk/dr-richard-barker/|publisher=CASMI|accessdate=2013-02-11}}</ref> | |||
| ==Education== | == Education == | ||
| ⚫ | Richard Barker was educated at Alleyn's School, London and Exeter College Oxford, where he received a ] in Chemistry. Following completion of his degree, he researched biological applications of ]s in pursuit of an Oxford ] and in post-doctoral studies in ], Germany and ].{{cn|date=February 2013}} | ||
| ⚫ | |||
| ==Career== | ==Career== | ||
| ⚫ | Barker's business career has included work in both Europe and the US.<ref name=Bloomberg>{{cite web|title=Richard W. Barker D.Phil., B.A., M.A.|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=436430&ticker=ICO:CN&previousCapId=23112550&previousTitle=ICO%20THERAPEUTICS%20INC|publisher=Investing.businessweek.com|accessdate=2013-02-11}}</ref> After a period with ],{{dn|date=February 2013}} in which he headed the European Healthcare practice and advised UK, Swiss and US pharmaceutical companies,{{cn|date=February 2013}} he held a succession of senior appointments in the US. As General Manager of ]'s healthcare business,{{cn|date=February 2013}} he launched Healthvillage, one of the earliest Internet healthcare applications.{{cn|date=February 2013}} At ],{{dn|date=February 2013}} he headed the diagnostics business, which brought the latest ] to market.{{cn|date=February 2013}} He subsequently served as chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.{{cn|date=February 2013}} | ||
| ⚫ | On returning to the UK, he headed the ] (ABPI) for six years<ref name=PMLive>{{cite web|title=Former ABPI head Richard Barker joins Aegate as senior adviser|url=http://www.pmlive.com/pharma_news/abpi_richard_barker_aegate_michael_peace_355981|publisher=Pmlive.com|accessdate=2013-02-11}}</ref> and initiated policy programmes in stratified medicine, while also launching frameworks for translational partnerships between academia and industry.{{cn|date=February 2013}} He formed and chairs Stem Cells of Safer Medicines,{{cn|date=February 2013}} a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity. | ||
| ⚫ | |||
| ⚫ | With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.{{cn|date=February 2013}} | ||
| ⚫ | On returning to the UK, he headed the ] (ABPI)<ref name=PMLive>{{cite web|title=Former ABPI head Richard Barker joins Aegate as senior adviser|url=http://www.pmlive.com/pharma_news/abpi_richard_barker_aegate_michael_peace_355981|publisher= |
||
| ⚫ | He chairs the South London Academic Health Science Network,{{cn|date=February 2013}} which aims to improve the quality and consistency of care in that part of the ] (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.{{cn|date=February 2013}} | ||
| ⚫ | With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation |
||
| == Board memberships == | |||
| He has been elected to the ] board of directors.<ref name=reuters>{{cite news|last=Press release|title=Celgene Corporation Elects Dr. Richard W. Barker to Its Board of Directors|url=http://www.reuters.com/article/2012/01/23/idUS79165+23-Jan-2012+BW20120123|accessdate=11 February 2013|newspaper=Reuters|date=23 January 2012}}</ref> | |||
| * ]<ref>http://www.innovationdebate.com/debate/panelists/dr-richard-barker/</ref> | |||
| == Published works == | |||
| ⚫ | He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the ], and to facilitate innovations emerging from academic and industrial research into NHS application. | ||
| ;Books | |||
| * Barker, Richard (2010). ''2030: the Future of Medicine'', Oxford University Press, 118 pages. ISBN 978-0199600663 | |||
| ;Articles | |||
| * Barker, Richard W.; and Sarah Garner. "Adaptive drug development and licensing", ''Regulatory Rapporteur'', Vol 9, No 10, page 13, October 2012. | |||
| * Barker, Richard. "A flexible blueprint for the future of drug development", ''The Lancet'', Volume 375, Issue 9712, pages 357-359, 30 January 2010. | |||
| ==Sample publications== | |||
| *2030 - the Future of Medicine <ref>http://2030healthfutures.com/</ref> | |||
| *"Adaptive drug development and licensing", Richard Barker & Sarah Garner, in ''Regulatory Rapporteur'', Vol 9, No 10, October 2012.<ref>http://www.aptivsolutions.com/wp-content/uploads/2012/09/Regulatory-Rapporteur-October-2012.pdf, Regulatory Rapporteur, coauthored with Sarah Garner</ref> | |||
| *"A flexible blueprint for the future of drug development", Richard Barker, ''Lancet''. January 2010<ref>{{cite web|author=Richard Barker a |url=http://www.lancet.com/journals/lancet/article/PIIS0140-6736(10)60141-9/fulltext |title=A flexible blueprint for the future of drug development |publisher=The Lancet |date= |accessdate=2013-01-28}}</ref> | |||
| * | |||
| ==Personal Life== | |||
| Richard lives in London, is married to Michaela Barker and has three children and a number of grandchildren. He enjoys mountain walking and music. | |||
| ==References== | ==References== | ||
| {{Reflist}} | {{Reflist}} | ||
| ] | ] | ||
Revision as of 21:48, 19 February 2013
 | This biography of a living person needs additional citations for verification. Please help by adding reliable sources. Contentious material about living persons that is unsourced or poorly sourced must be removed immediately from the article and its talk page, especially if potentially libelous. Find sources: "Richard Barker" businessman – news · newspapers · books · scholar · JSTOR (February 2013) (Learn how and when to remove this message) |
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. Please help improve it by replacing them with more appropriate citations to reliable, independent, third-party sources. (February 2013) (Learn how and when to remove this message) |
Richard Barker is a British healthcare professional. He is known as the Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI).
Education
Richard Barker was educated at Alleyn's School, London and Exeter College Oxford, where he received a Bachelor's degree in Chemistry. Following completion of his degree, he researched biological applications of magnetic resonance techniques in pursuit of an Oxford DPhil and in post-doctoral studies in Munich, Germany and Leeds, England.
Career
Barker's business career has included work in both Europe and the US. After a period with McKinsey, in which he headed the European Healthcare practice and advised UK, Swiss and US pharmaceutical companies, he held a succession of senior appointments in the US. As General Manager of IBM's healthcare business, he launched Healthvillage, one of the earliest Internet healthcare applications. At Chiron, he headed the diagnostics business, which brought the latest immunodiagnostics to market. He subsequently served as chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.
On returning to the UK, he headed the Association of the British Pharmaceutical Industry (ABPI) for six years and initiated policy programmes in stratified medicine, while also launching frameworks for translational partnerships between academia and industry. He formed and chairs Stem Cells of Safer Medicines, a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.
With colleagues in Oxford and UCL, he has formed CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.
He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the National Health Service (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.
Board memberships
Published works
- Books
- Barker, Richard (2010). 2030: the Future of Medicine, Oxford University Press, 118 pages. ISBN 978-0199600663
- Articles
- Barker, Richard W.; and Sarah Garner. "Adaptive drug development and licensing", Regulatory Rapporteur, Vol 9, No 10, page 13, October 2012.
- Barker, Richard. "A flexible blueprint for the future of drug development", The Lancet, Volume 375, Issue 9712, pages 357-359, 30 January 2010.
References
- "Dr Richard Barker OBE". CASMI. Retrieved 2013-02-11.
- "Richard W. Barker D.Phil., B.A., M.A." Investing.businessweek.com. Retrieved 2013-02-11.
- "Former ABPI head Richard Barker joins Aegate as senior adviser". Pmlive.com. Retrieved 2013-02-11.
- http://www.innovationdebate.com/debate/panelists/dr-richard-barker/